Investment Opportunity
The portable diagnostics
market is ready
BracyInsight™ sits at the intersection of three high-growth markets: computational medicine, AI healthcare, and military medicine. We are seeking strategic investors who understand the magnitude of this opportunity.
Market Opportunity
Three converging markets
Portable Diagnostics
$45B+
8.4% CAGR
Global portable diagnostics market driven by decentralization of healthcare, aging populations, and demand for point-of-care testing.
AI in Healthcare
$188B+
37% CAGR
AI healthcare market expanding rapidly as clinical AI moves from research to deployment across diagnostics, imaging, and decision support.
Military Medicine
$8.5B+
5.2% CAGR
Defense health programs investing heavily in point-of-injury diagnostics, TCCC technology, and autonomous medical systems for future warfare.
Investment Thesis
What investors want to know
Problem
Preventable deaths from delayed diagnosis in battlefield, emergency, and rural settings. Existing solutions are too bulky, too expensive, or require specialist operators.
Market
Three converging markets totaling $240B+ by 2030. First-mover advantage in AI-powered portable multi-modal diagnostics for austere environments.
Technology
Hardware-agnostic computational physiology platform. The innovation is the software, algorithms, and physiological modeling — not the sensing hardware. High barriers to replication due to algorithm IP and clinical data moats.
Team
Founder brings clinical data expertise, statistical programming, regulatory knowledge, and healthcare analytics experience — rare combination in hardware startups.
Milestones
Prototype development → clinical validation → FDA 510(k) submission → SBIR Phase I/II → commercial deployment. 24-month roadmap to working prototype.
Funding
Seeking seed capital for prototype development and clinical validation. Parallel SBIR/STTR applications targeting DoD and NIH programs.
Funding Strategy
Multiple funding pathways
SBIR/STTR
DoD and NIH Small Business Innovation Research grants for prototype development and clinical validation. Non-dilutive funding pathway.
Angel Funding
Strategic angel investors with healthcare, defense, or technology backgrounds who can provide capital and domain expertise.
Seed Investment
Institutional seed round to fund prototype completion, regulatory strategy, and initial clinical partnerships.
Strategic Partners
Defense contractors, health systems, and medical device companies seeking to integrate or license the BracyInsight™ Computational Physiology Platform.
Current Status
Where we are today
Concept validation and technology feasibility assessment
Seeking strategic advisors (trauma surgeon, radiologist, biomedical engineer)
Seeking technical partners and clinical collaborators
SBIR/STTR application preparation
Prototype development — target Q4 2026
Clinical validation studies — target 2027
FDA 510(k) submission — target 2028
Ready to learn more?
Contact us to request our investor brief, discuss partnership opportunities, or schedule a call with the founding team.
Request Investor Brief